SGLT2 versus DPP4 inhibitors for type 2 diabetes

Presently, choosing between a SGLT2 inhibitor and a DPP4 inhibitor to manage hyperglycaemia in type 2 diabetes is difficult: each pharmacological class has advantages and disadvantages. The clinical results of large, long-term, prospective placebo-controlled trials assessing cardiovascular outcomes, presently in progress with DPP4 inhibitors and SGLT2 inhibitors will help guide clinicians further (The Lancet)